Daily NSE closing prices — this stock isn't in the live-tracked universe yet.
NSE Close — 19 Nov 2026
₹479.5
Change
+9.1 (1.93%)
Open
₹469.0
Prev. Close
₹470.4
Day High
₹479.5
Day Low
₹469.0
Volume Analysis
Traded
9,007
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (4)
- •Low return on equity (-6.18%)
- •Promoter holding is falling
- •Below-average fundamentals quality score (47/100)
- •Low operating margin (2.9%)
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹493.5 | ₹486.5 | ₹483.0 | ₹476.0 | ₹472.5 | ₹465.5 | ₹462.0 |
| Fibonacci | ₹486.5 | ₹482.49 | ₹480.01 | ₹476.0 | ₹471.99 | ₹469.51 | ₹465.5 |
| Camarilla | ₹482.39 | ₹481.43 | ₹480.46 | ₹476.0 | ₹478.54 | ₹477.58 | ₹476.61 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+223.13%
1 Week
-2.51%
1 Month
+3.98%
3 Months
+97.77%
6 Months
+255.11%
1 Year
+186.97%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
-46.86%
Net margin -57.14% × asset turnover 0.59x × equity multiplier 1.39x
Company Overview
Sector
Healthcare
Market Cap
₹1,121 Cr
ROE
-6.18%
Book Value
₹216.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.
TopFund Analysis
Bafna Pharmaceuticals Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 47/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (-6.18%); promoter holding is falling. FII holding has been rising.
TopFund Score — Fundamentals Quality
47/100 — WeakData confidence: 72/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- +Company is almost debt free.
- +Debtor days have improved from 151 to 51.8 days.
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of -15.2% over past five years.
- −Company has a low return on equity of -63.9% over last 3 years.
- −Working capital days have increased from -77.3 days to 90.4 days
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
We herewith enclose the Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter & Half Year ended September 30, 2026 as …
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2018 | Sep 2018 | Jun 2019 | Sep 2019 | |
|---|---|---|---|---|
| Sales + | 12 | 9 | 7 | 12 |
| Expenses + | 14 | 9 | 10 | 12 |
| Operating Profit | -2 | 0 | -3 | 0 |
| OPM % | -15.23% | 2.04% | -41.75% | -3.28% |
| Other Income + | 0 | 0 | 0 | 1 |
| Interest | 1 | 1 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 |
| Profit before tax | -4 | -1 | -4 | -1 |
| Tax % | -1.12% | 4.1% | -42.59% | 7.27% |
| Net Profit + | -4 | -1 | -2 | -1 |
| EPS in Rs | -1 | -1 | -1 | -2 |
| Raw PDF | — | — | — | — |
| YoY Sales growth | — | — | -43 | 31 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 129 | 175 | 185 | 97 | 85 | 65 | 46 | 44 | 42 |
| Expenses + | 110 | 153 | 162 | 114 | 85 | 71 | 81 | 57 | 41 |
| Operating Profit | 19 | 22 | 23 | -18 | 1 | -6 | -35 | -13 | 1 |
| OPM % | 15.0% | 13.0% | 12.0% | -18.0% | 0.6% | -9.0% | -77.0% | -30.0% | 2.9% |
| Other Income + | 1 | 3 | 2 | 43 | 2 | 1 | 31 | 1 | -22 |
| Interest | 8 | 12 | 13 | 13 | 13 | 11 | 7 | 2 | 0 |
| Depreciation | 6 | 8 | 9 | 6 | 5 | 4 | 4 | 3 | 3 |
| Profit before tax | 5 | 5 | 2 | 6 | -15 | -20 | -15 | -17 | -24 |
| Tax % | 64.0% | 27.0% | 42.0% | -2.0% | -1.0% | -4.0% | 15.0% | 6.0% | 0.0% |
| Net Profit + | 2 | 4 | 1 | 6 | -15 | -19 | -17 | -18 | -24 |
| EPS in Rs | 1 | 2 | 1 | 3 | -8 | -10 | -7 | -8 | -105 |
| Dividend Payout % | 0.0% | 28.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Sales growth | — | 36 | 5 | -48 | -12 | -24 | -30 | -4 | -3 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
|---|---|---|---|---|---|---|---|---|---|
| Reserves | 45 | 49 | 50 | 53 | 39 | 24 | 14 | -5 | 49 |
| Borrowings + | 85 | 100 | 108 | 69 | 80 | 82 | 47 | 46 | 3 |
| Other Liabilities + | 70 | 93 | 59 | 59 | 54 | 53 | 54 | 54 | 17 |
| Total Liabilities | 219 | 261 | 236 | 200 | 193 | 178 | 138 | 119 | 71 |
| Fixed Assets + | 76 | 73 | 69 | 55 | 53 | 49 | 45 | 37 | 35 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 17 | 17 | 17 | 0 | 0 | 0 |
| Other Assets + | 143 | 188 | 167 | 128 | 123 | 113 | 93 | 82 | 36 |
| Total Assets | 219 | 261 | 236 | 200 | 193 | 178 | 138 | 119 | 71 |
| Equity Capital | 18 | 19 | 19 | 19 | 19 | 19 | 24 | 24 | 2 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 29 | 37 | 2 | 11 | 1 | -1 | -7 | -2 | -34 |
| Cash from Investing Activity + | -38 | -6 | -7 | 60 | 0 | -5 | 38 | 15 | 33 |
| Cash from Financing Activity + | -1 | -12 | -13 | -71 | -1 | 6 | -31 | -14 | 7 |
| Net Cash Flow | -9 | 19 | -18 | 0 | 0 | 0 | 0 | 0 | 6 |
| Free Cash Flow | -1 | 34 | 0 | 44 | -1 | -1 | 40 | 3 | -36 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 161 | 167 | 9 | -73 | 175 | 16 | 20 | 14 | -2,812 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 11.57% | 11.7% | 11.71% | 11.7% | 11.7% | 16.47% | 15.66% | 15.66% | 15.66% | 15.66% | 15.66% | 15.66% |
| Promoters | 88.42% | 88.29% | 88.29% | 88.29% | 88.29% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 8.53% | 9.34% | 9.34% | 9.34% | 9.34% | 9.34% | 9.34% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Bafna Pharmaceuticals Ltd (this stock) | 1,121 | — | 2.19 | -6.18% |
| Gpt Healthcare Limited | 1,136 | 27.3 | — | 28.5% |
| Sigachi Industries Ltd | 1,088 | 41.3 | 2.02 | 5.78% |
| 3b Blackbio Dx Ltd. | 1,157 | 19.7 | 3.33 | 19.8% |
| Laxmi Dental Limited | 1,076 | 29.7 | 4.05 | 14.8% |
| Lincoln Pharma Ltd | 1,032 | 10.6 | 1.27 | 12.0% |
| Gujarat Kidney N Sup Sp L | 1,269 | 66.8 | 4.82 | 11.1% |
Which Mutual Funds Hold Bafna Pharmaceuticals Ltd?
Frequently Asked Questions about Bafna Pharmaceuticals Ltd
Bafna Pharmaceuticals Ltd (BAFNAPH) closed at ₹479.5 on NSE on 19 November 2026, up 9.1 (1.93%) from the previous close.
Bafna Pharmaceuticals Ltd trades on the NSE (National Stock Exchange of India) under the symbol BAFNAPH.
Bafna Pharmaceuticals Ltd has a dividend yield of 0.0%.
Bafna Pharmaceuticals Ltd's 52-week high is ₹504.0 and its 52-week low is ₹94.8.
Bafna Pharmaceuticals Ltd has a market capitalisation of ₹1,121 crore.
Bafna Pharmaceuticals Ltd has a TopFund Quality Score of 47/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Bafna Pharmaceuticals Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.